Akebia initiates post-marketing study to identify benefits of Vafseo

Akebia (AKBA) Therapeutics announced the initiation of a post-marketing study to identify additional potential benefits of Vafseo. The VOCAL trial, conducted within DaVita clinics, aims to generate data to evaluate the efficacy and safety of three times per week dosing of vadadustat compared to standard of care erythropoiesis-stimulating agents, ESA, in patients with anemia of CKD receiving in-center hemodialysis. “Our team and partners within the dialysis community share a commitment to improving patient care,” said Steven K. Burke, M.D., Chief Medical Officer of Akebia. “The VOCAL trial, conducted within DaVita clinics, enables us to continue building the body of evidence on the effectiveness of Vafseo when dosed three times a week as well as to understand the potential additional benefits of Vafseo treatment for anemia in CKD patients.”